https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/funding-provided-develop-new-therapy-acute-liver-failure/
Funding provided to develop new therapy for acute liver failure
9 Sep 2015, 4:50 p.m.
BRC-supported researcher Dr Kevin Mills has been awarded funding from the NIHR to investigate the regenerative ability of the liver following acute liver failure (ALF). If successful, the team hope that their research will lead to a novel therapy that could buy patients enough time to allow their livers to regenerate naturally, avoiding the need for liver transplantsThis research will be led by Professor Anil Dhawan at Kings College London in collaboration with Dr Mills at UCL Institute of Child Health. Specifically, the team aim to develop a novel technique where human liver cells grown in the lab are encapsulated in a material called alginate and delivered to a patient to help their ailing liver regenerate. Encasing the liver cells in alginate is particularly important as it reduces the need for immunosuppression.
Studies in the lab will focus on the feasibility of this novel therapy under lab conditions.
New trial to support childhood survivors of brain tumours
Experts at Great Ormond Street Hospital have launched the first trial of its kind to support children’s cognitive development following treatment for a brain tumour.
Professor Waseem Qasim named in list of leading global health leaders
Professor Waseem Qasim, Consultant at GOSH and Professor of Cell and Gene Therapy at University College London has been named in TIME magazine’s 2026 TIME100 Health List of the World’s Most Influential Leaders in Health.
Alyssa Tapley named in list of leading global health leaders
GOSH patient, Alyssa Tapley, 17 from Leicester, has been named in TIME’S 2026 TIME100 Health List of the World’s Most Influential Leaders in Health.
GOSH joins partnership to boost early diagnosis and deliver better treatments
GOSH is partnering with LifeArc to set up KidsRare - a new initiative to help deliver more tests and treatments for children living with a rare disease.